-+ 0.00%
-+ 0.00%
-+ 0.00%

TONIX PHARMACEUTICALS ANNOUNCES FIRST PATIENT ENROLLED IN PHASE 2 HORIZON STUDY OF TNX-102 SL FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)

Reuters·06/29/2026 11:25:29

Please log in to view news